Pharmasset, Inc. to Challenge Vertex Pharmaceuticals (MA) Hepatitis C Treatment, BMO Says

Bloomberg -- Pharmasset Inc. (VRUS)’s experimental hepatitis C therapies may pose a challenge to treatments from Vertex Pharmaceuticals Inc. (VRTX), based on trial results to be released in late March, BMO Capital Markets Corp. analysts said.